Fig. 3From: Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphomaComparison of GFR between the subgroups. The diagram summarizes the development of median GFR in the course of therapy subdivided by the number of R-DHAP cycles receivedBack to article page